Abstract
Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Current Aging Science
Title: The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Volume: 1 Issue: 2
Author(s): R. A. Armstrong
Affiliation:
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Abstract: Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Export Options
About this article
Cite this article as:
Armstrong A. R., The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders, Current Aging Science 2008; 1 (2) . https://dx.doi.org/10.2174/1874609810801020122
DOI https://dx.doi.org/10.2174/1874609810801020122 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Pentameric models as alternative molecular targets for the design of new antiaggregant agents
Current Protein & Peptide Science Preface
Current Psychopharmacology The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds
Current Pharmaceutical Design Interactions Between Apo E and Amyloid Beta and their Relationship to Nutriproteomics and Neurodegeneration
Current Proteomics Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry